Introduction

stands as the undisputed gold standard for infant nutrition, providing an unparalleled combination of essential nutrients, immunological protection, and developmental support that synthetic formulas have yet to fully replicate. This biological fluid represents a dynamic, living substance that adapts to the changing needs of growing infants, containing not just fundamental nutritional components but also complex bioactive molecules that shape infant health in profound ways. Among these remarkable constituents, Human Milk Oligosaccharides () have emerged as particularly crucial elements that distinguish human milk from other mammalian milks and infant formulas. These complex carbohydrates, while not directly nutritious to the infant, serve as powerful prebiotics and immune modulators that establish the foundation for lifelong health.

The composition of breast milk represents a sophisticated biological system that includes macronutrients like proteins for growth, fats for energy and brain development, and carbohydrates for immediate energy needs. Beyond these fundamental components, breast milk contains a diverse array of micronutrients, living immune cells, antibodies, enzymes, and hormones that work in concert to support infant development. However, it is the HMOs that have captured scientific attention in recent decades due to their unique structural complexity and multifunctional benefits. With over 200 different structures identified to date, these complex sugar molecules constitute the third most abundant solid component in human milk after lactose and lipids, highlighting their biological significance.

The scientific community has increasingly recognized that HMOs function as sophisticated signaling molecules that influence multiple aspects of infant health, particularly gut microbiome development, immune system education, and protection against pathogens. Unlike other milk components, HMOs resist digestion in the upper gastrointestinal tract and reach the colon intact, where they selectively nourish beneficial bacteria while inhibiting the growth of harmful microorganisms. This selective promotion of bifidobacteria and other commensal bacteria creates a healthy gut environment that reduces the risk of infectious diseases, allergic conditions, and even metabolic disorders later in life. The appropriate of HMOs in infant nutrition has become a subject of intense research, as scientists strive to understand the optimal concentrations needed to replicate these benefits in formula-fed infants.

Composition of Breast Milk: An Overview

Breast milk represents a remarkably complex biological fluid whose composition evolves throughout lactation to meet the changing nutritional and developmental needs of the growing infant. The macronutrient profile includes proteins such as casein and whey, which provide essential amino acids for tissue building and contain bioactive peptides with antimicrobial and immunomodulatory properties. The fat content in breast milk serves as the primary energy source, contributing approximately 50% of the total calories, while also delivering fat-soluble vitamins and essential fatty acids crucial for brain development and visual acuity. Carbohydrates, predominantly in the form of lactose, supply readily available energy and enhance calcium absorption, but it is the complex oligosaccharides that distinguish human milk from other mammalian milks.

Beyond macronutrients, breast milk contains a comprehensive profile of micronutrients including vitamins A, D, E, K, and the full spectrum of B vitamins, along with essential minerals like iron, zinc, calcium, and selenium in highly bioavailable forms. These micronutrients support various metabolic processes, bone development, antioxidant defense, and neurological function. Perhaps even more remarkable are the immunological components present in breast milk, including secretory IgA antibodies that provide targeted protection against pathogens in the infant's environment, living immune cells such as macrophages and lymphocytes that actively combat infection, and anti-inflammatory cytokines that help regulate immune responses.

Human Milk Oligosaccharides (HMOs) constitute a particularly fascinating component of breast milk, with concentrations ranging from 5-15 g/L in mature milk and even higher levels in colostrum. These complex sugar molecules are synthesized in the mammary gland from five basic monosaccharide building blocks: glucose, galactose, N-acetylglucosamine, fucose, and sialic acid. The structural diversity of HMOs arises from various linkages between these building blocks, creating both neutral and acidic oligosaccharides with distinct biological functions. Among the most abundant HMOs are 2'-fucosyllactose (2'-FL), lacto-N-neotetraose (LNnT), and 6'-sialyllactose (6'-SL), each demonstrating specific benefits for infant health. Recent research from Hong Kong has shown that the concentration and profile of HMOs in breast milk can vary significantly among different populations, with studies indicating that Chinese mothers typically exhibit higher levels of certain fucosylated HMOs compared to Western populations, potentially reflecting genetic and dietary influences.

• Proteins: Casein (40%), whey (60%) with immunoglobulins, lactoferrin, lysozyme
• Fats: Triglycerides (98%), phospholipids, cholesterol, long-chain polyunsaturated fatty acids
• Carbohydrates: Lactose (primary), Human Milk Oligosaccharides (HMOs)
• Micronutrients: Fat-soluble and water-soluble vitamins, minerals in highly bioavailable forms
• Immunological factors: Secretory IgA, IgG, IgM, leukocytes, cytokines, growth factors
• HMOs: Over 200 identified structures with prebiotic, anti-adhesive, and immunomodulatory functions

Variability of HMO Composition in Breast Milk

The composition and concentration of HMOs in breast milk demonstrate remarkable variability among different mothers, influenced by a complex interplay of genetic, environmental, and physiological factors. This natural variation creates a personalized nutritional profile that may be uniquely suited to the specific needs of each infant. The most significant determinant of HMO diversity is maternal genetics, particularly the secretor status controlled by the FUT2 gene. Approximately 70-80% of women are secretors, meaning they produce active α1-2-fucosyltransferase enzyme that adds fucose residues to HMO structures, resulting in high concentrations of α1-2-fucosylated HMOs like 2'-FL. Non-secretor mothers (20-30% of the population) lack this enzyme activity and consequently produce milk with absent or dramatically reduced levels of these specific HMOs, while compensating with higher concentrations of other oligosaccharides such as lacto-N-neotetraose and sialylated species.

Maternal diet and lifestyle factors also significantly influence HMO profiles, though the mechanisms are not yet fully understood. Research suggests that nutritional status, particularly carbohydrate intake, may affect the overall concentration of HMOs in breast milk. A recent study conducted in Hong Kong demonstrated that mothers with higher consumption of fruits, vegetables, and whole grains tended to have more diverse HMO profiles, while those with diets high in processed foods showed reduced HMO complexity. Additionally, factors such as maternal body mass index, mode of delivery, and even stress levels have been correlated with variations in HMO composition. Environmental exposures, including geographic location and seasonal changes, further contribute to this variability, with studies noting differences in HMO patterns between populations in different regions of the world.

The stage of lactation represents another critical factor influencing HMO composition, with concentrations typically highest in colostrum and gradually decreasing throughout lactation, though the relative proportions of individual HMOs may change over time. Preterm delivery also significantly alters HMO profiles, with milk from mothers delivering prematurely often containing higher concentrations of certain sialylated HMOs that may specifically support the vulnerable preterm infant's developing brain and immune system. The impact of HMO variability on infant health outcomes is substantial, with research indicating that specific HMO patterns correlate with reduced incidence of infectious diseases, allergic conditions, and necrotizing enterocolitis in premature infants. Understanding this natural variability is crucial for determining the appropriate addition amount of specific HMOs in infant formulas to better mimic the protective effects of breast milk.

Factors Influencing HMO Composition

The complex interplay of factors determining HMO composition creates a highly personalized milk profile for each mother-infant dyad. Genetic factors, primarily secretor status, establish the foundational HMO pattern, while modifiable factors like diet and lifestyle introduce additional layers of variation. The lactation stage dynamically shapes HMO concentrations, with colostrum containing the highest levels that gradually decrease as lactation progresses, though certain HMOs may show transient increases during specific periods. Gestational age at delivery significantly influences HMO profiles, with preterm milk often containing protective HMO patterns tailored to the vulnerable premature infant's needs.

Research from Asian populations, including studies in Hong Kong, has revealed distinctive HMO profiles compared to Western populations, with higher prevalence of certain fucosylated HMOs that may offer enhanced protection against specific pathogens common in these regions. These population-specific patterns highlight the evolutionary adaptation of breast milk composition to local environmental challenges. The understanding of these influencing factors is increasingly important as researchers work to develop targeted nutritional interventions, including determining the optimal addition amount of specific HMOs in infant formulas for different population groups and individual needs.

The Secretor Status and HMO Production

The secretor status, determined by polymorphisms in the fucosyltransferase 2 (FUT2) gene, represents the most significant genetic factor influencing HMO composition in breast milk. This gene encodes the α1-2-fucosyltransferase enzyme responsible for adding fucose molecules in α1-2 linkage to the oligosaccharide backbone, producing what are known as α1-2-fucosylated HMOs. Approximately 70-80% of women are secretors who possess at least one functional FUT2 allele and consequently produce milk rich in 2'-fucosyllactose (2'-FL) and other fucosylated HMOs. The remaining 20-30% are non-secretors with two non-functional FUT2 alleles who completely lack the ability to produce α1-2-fucosylated HMOs, resulting in a distinctly different HMO profile.

The differences in HMO profiles between secretor and non-secretor mothers are profound and have significant implications for infant health. Secretor milk typically contains high concentrations of 2'-FL, which has been extensively studied for its ability to protect against specific pathogens by acting as a decoy receptor that prevents bacterial adhesion to intestinal epithelial cells. Additionally, lacto-N-fucopentaose I (LNFP I) and lactodifucotetraose (LDFT) are abundant in secretor milk, contributing to its prebiotic and immunomodulatory properties. In contrast, non-secretor milk is characterized by the absence of these α1-2-fucosylated HMOs but contains compensatory higher levels of non-fucosylated neutral HMOs like lacto-N-tetraose (LNT) and lacto-N-neotetraose (LNnT), as well as increased concentrations of sialylated HMOs such as 3'-sialyllactose (3'-SL) and 6'-sialyllactose (6'-SL).

The implications of secretor status for infant health and gut microbiome development are substantial and well-documented. Numerous studies have demonstrated that infants fed secretor milk typically develop gut microbiomes dominated by Bifidobacterium species, particularly B. longum subsp. infantis, which specializes in HMO consumption. This bifidobacterial dominance is associated with reduced incidence of diarrheal diseases, respiratory infections, and necrotizing enterocolitis in preterm infants. In contrast, infants receiving non-secretor milk often exhibit more diverse gut microbiomes with higher abundance of Bacteroides species that utilize different HMO structures. Research from Hong Kong has shown that secretor status may influence susceptibility to specific pathogens, with non-secretor infants demonstrating higher risk of certain bacterial infections but potentially lower risk of others, highlighting the complex relationship between HMO profiles and pathogen specificity.

Genetic and Functional Implications

The genetic determination of secretor status creates a natural experiment in human milk composition that has provided invaluable insights into HMO functions. Beyond the FUT2 gene, other genetic polymorphisms in fucosyltransferase and sialyltransferase genes further contribute to the diversity of HMO profiles among women. The functional consequences of these genetic differences extend beyond infant gut microbiome composition to influence immune system development, metabolic programming, and even cognitive outcomes. Understanding these genetic influences is crucial for developing personalized infant nutrition strategies, including determining the appropriate addition amount of specific HMOs in formulas for infants who would otherwise receive non-secretor milk.

Benefits of HMOs for Different Infants

The multifaceted benefits of HMOs extend to all infants but manifest differently depending on gestational age, health status, and individual susceptibility to various conditions. For premature infants, who face unique challenges due to their physiological immaturity, HMOs provide critical support for gut development, immune protection, and neurological maturation. The gut of premature infants is particularly vulnerable to inflammatory conditions like necrotizing enterocolitis (NEC), a serious gastrointestinal emergency with high mortality rates. Multiple studies have demonstrated that specific HMOs, particularly disialyllacto-N-tetraose (DSLNT), significantly reduce the incidence of NEC in preterm infants by strengthening gut barrier function, modulating inflammatory responses, and preventing pathogenic bacterial translocation. Additionally, sialylated HMOs abundant in preterm milk serve as important building blocks for brain development and cognitive function, as sialic acid is a crucial component of gangliosides and synaptic structures in the developing brain.

For healthy term infants, HMOs provide comprehensive protection against infectious diseases while supporting the appropriate maturation of the immune system. The prebiotic effect of HMOs selectively stimulates the growth of beneficial Bifidobacterium and Bacteroides species, creating a gut environment that resists colonization by pathogens. Beyond this microbiome-mediated protection, many HMOs function as receptor analogs that directly inhibit the adhesion of specific viruses, bacteria, and protozoa to intestinal epithelial cells, effectively preventing infection before it can establish. This anti-adhesive property has been demonstrated against numerous pathogens including Campylobacter jejuni, Salmonella fyris, and caliciviruses that cause diarrheal diseases. Furthermore, HMOs influence immune development beyond the gut, with research showing that they can modulate systemic immune responses and reduce the risk of respiratory infections and otitis media.

Emerging evidence suggests that HMOs may offer particular benefits for infants with specific health conditions or genetic predispositions. For infants with family history of allergic diseases, certain HMO profiles have been associated with reduced risk of developing atopic dermatitis, food allergies, and asthma, likely through their influence on immune maturation and gut barrier integrity. For infants born via cesarean section, who typically experience delayed colonization with beneficial bacteria, HMOs may help accelerate the development of a healthy microbiome. The potential therapeutic applications of HMOs are expanding, with ongoing research investigating their role in preventing obesity, optimizing neurodevelopment in infants with neurological risk factors, and even supporting infants with specific metabolic disorders. As our understanding of these benefits grows, so does the importance of determining the optimal addition amount of specific HMOs in specialized infant formulas for vulnerable populations.

Population-Specific Considerations

The benefits of HMOs must be considered within the context of population-specific factors including genetic background, environmental exposures, and feeding practices. Research in Asian populations, including studies in Hong Kong, has revealed distinctive patterns of HMO benefits that may reflect co-evolution with regional pathogens and dietary practices. For instance, the high prevalence of secretor status and corresponding high levels of 2'-FL in Asian populations may provide enhanced protection against specific pathogens endemic to these regions. Understanding these population-specific patterns is crucial for developing targeted nutritional interventions that optimize HMO benefits for different infant populations around the world.

Conclusion

The remarkable complexity and variability of Human Milk Oligosaccharides in breast milk underscore the sophisticated biological system that has evolved to support infant health and development. These multifunctional compounds represent a key distinction between human milk and other mammalian milks or infant formulas, providing prebiotic, anti-infective, and immunomodulatory benefits that extend far beyond basic nutrition. The natural variation in HMO composition among different mothers, influenced primarily by genetic factors like secretor status but also by diet, lifestyle, and stage of lactation, creates a personalized nutritional profile that may be uniquely suited to each infant's specific needs. This individualization highlights the incredible adaptability of human milk as a dynamic, responsive biological fluid that cannot be fully replicated by standardized formulas.

The implications of HMO research extend to multiple domains of infant health, from protection against infectious diseases to programming of the immune system and metabolic pathways. The growing understanding of how specific HMOs function has enabled the development of supplemented infant formulas containing the most abundant HMOs like 2'-FL and LNnT, though the incredible structural diversity of naturally occurring HMOs presents ongoing challenges for complete replication. Future research directions should focus on understanding the functions of less abundant HMOs, exploring synergistic effects between different oligosaccharides, and investigating how HMO composition adapts to specific infant needs and environmental challenges. Particular attention should be paid to determining the optimal addition amount of specific HMOs or HMO combinations for different infant populations, including those with specific health conditions or genetic backgrounds.

As scientific knowledge advances, the potential applications of HMO research continue to expand, offering promising avenues for improving infant health outcomes through targeted nutritional interventions. The ongoing study of breast milk composition, particularly HMOs, not only deepens our appreciation for the biological sophistication of human milk but also provides critical insights for developing next-generation infant nutrition products that more closely mimic the gold standard of breast milk. Ultimately, this research underscores the importance of supporting breastfeeding while simultaneously working to improve alternatives for situations where breastfeeding is not possible, ensuring that all infants have access to the profound benefits these remarkable compounds provide.